Amerise Biosciences News

Amerise Biosciences Appoints New CFO & Whole-time Director

Amerise Biosciences Limited announced key leadership changes with Albert Hines appointed as Whole-time Director and CFO, replacing Dinesh Rathod who resigned due to personal commitments on February 2, 2026.

Amerise Biosciences Reports Quarterly Financial Results for September 2025

Amerise Biosciences Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The company reported total income of Rs. 6.78 lakhs for the quarter, consisting entirely of other income with no revenue from operations. Total expenses amounted to Rs. 10.98 lakhs, including employee benefit expenses of Rs. 1.80 lakhs and other expenses of Rs. 9.18 lakhs, resulting in a net loss after tax of Rs. 4.20 lakhs. The Board of Directors approved these results in a meeting held on November 5, 2025. The company operates in a single business segment and has undergone a limited review by statutory auditors.

Amerise Biosciences Reports Net Loss of Rs. 0.81 Lacs in Latest Quarter

Amerise Biosciences Limited reported a net loss of Rs. 0.81 lacs for the quarter ended June 30, 2025, compared to a profit of Rs. 10.59 lacs in the previous quarter. Total income declined to Rs. 6.37 lacs from Rs. 18.80 lacs in the previous quarter. The company's revenue came entirely from other operating revenue, with no gross revenue from product sales. Total expenses for the quarter were Rs. 7.18 lacs, primarily consisting of employee benefit expenses of Rs. 2.32 lacs and other expenses of Rs. 4.86 lacs. The company's paid-up equity share capital remained at Rs. 660.69 lacs. Basic and diluted earnings per share were both Rs. (0.00) for the quarter.